Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Roche's Cobas AmpliPrep/Cobas TaqMan HCV Test v2.0

Premium

Roche said this week that it has received approval from the US Food and Drug Administration for its Cobas AmpliPrep/Cobas TaqMan HCV Test, v2.0.

Roche's assay is designed to help manage patients with chronic hepatitis C virus infection, in conjunction with clinical and laboratory markers of infection. The test quantifies hepatitis C virus RNA genotypes 1 to 6 in human EDTA plasma or serum, and can be used to predict the probability of sustained virologic response early during a course of antiviral therapy and to assess viral response to antiviral treatment, as measured by changes of HCV RNA levels.

The real-time PCR-based assay is designed for use on Roche's fully automated Cobas AmpliPrep/Cobas TaqMan System, a platform for viral load monitoring of multiple infectious diseases. The system can be combined with the Cobas p 630 instrument, which provides an integrated pre-analytical primary tube handling solution.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.